The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes.
Adaptor Proteins, Signal Transducing
/ genetics
Animals
Antineoplastic Agents
/ therapeutic use
Carcinoma, Squamous Cell
/ drug therapy
Cetuximab
/ therapeutic use
Cisplatin
/ therapeutic use
Cohort Studies
Cornified Envelope Proline-Rich Proteins
/ genetics
Disease Models, Animal
Epithelial-Mesenchymal Transition
Glutathione Peroxidase
/ genetics
Head and Neck Neoplasms
/ drug therapy
Humans
Mice
RNA, Messenger
/ metabolism
Treatment Outcome
EFS
GPX2
SPRR1A
epithelial-like
gene-expression profile
head and neck cancer
mesenchymal-like
prognosis
survival
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
05
05
2017
revised:
28
11
2018
accepted:
12
12
2018
pubmed:
18
1
2019
medline:
11
11
2020
entrez:
18
1
2019
Statut:
ppublish
Résumé
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial-like (EL) or mesenchymal-like (ML) phenotypes. We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival. EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93-gene expression signature between ML and EL cells was used to build a three-gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA-seq data of the TCGA-HNSC project. Its prognostic value was confirmed in two independent cohorts. EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.
Sections du résumé
BACKGROUND
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial-like (EL) or mesenchymal-like (ML) phenotypes.
MATERIALS AND METHODS
We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.
RESULTS
EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93-gene expression signature between ML and EL cells was used to build a three-gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA-seq data of the TCGA-HNSC project. Its prognostic value was confirmed in two independent cohorts.
CONCLUSION
EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Antineoplastic Agents
0
Cornified Envelope Proline-Rich Proteins
0
EFS protein, human
0
RNA, Messenger
0
SPRR1A protein, human
0
GPX2 protein, human
EC 1.11.1.-
Glutathione Peroxidase
EC 1.11.1.9
Cetuximab
PQX0D8J21J
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1830-1845Subventions
Organisme : Instituto de Salud Carlos III
Pays : International
Organisme : CIBER-BBN
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.